Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Oct 26 - Oct 31
Rotate every single time
("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced that China's National Medical Products Administration (NMPA) has approved ecnoglutide injection for glycemic control in adults with type 2 diabetes mellitus (T2DM), making it the world's first approved cAMP-biased GLP-1 receptor agonist
Byetta (Injection) Indication : Type 2 Diabetes Frequency : Twice daily Bydureon BCise (Injection) Indication : Type 2 Diabetes Frequency : Weekly (Extended-release) 6
Scorecard: strongest in Access (5.0/5) and Authenticity (5.0/5)
Death Dis
